Genome engineering strategies, like CRISPR, result in heterogeneous outcomes including off-target edits, co-occurring multiplex edits, and variations in zygosity. These outcomes cannot be easily measured using traditional sequencing without lengthy clonal outgrowth steps and hours of computational work. With the Tapestri single-cell platform you can rapidly capture genome editing outcomes and confidently validate your engineered cell therapy or CRISPR-based disease model.
The Tapestri Genome Editing Solution is the end-to-end Tapestri workflow for single-cell genome editing analysis. A sample of cells containing heterogeneous genome edits is processed on the Tapestri Platform, sequenced using NGS, and analyzed using Tapestri Genome Editing software. The assessment at single-cell resolution of on-targets, predicted off-targets, zygosity of edits, co-occurring (multiplex) edits, predicted translocations and cell-surface proteins is possible.